MEC Signs RTO Definitive Agreement To Acquire Albert Labs, A European Psychedelic Drug Researcher & Developer
Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary psilocybin-based therapy for patients with urgent, unmet needs.
MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™
MagicMed Industries Inc. (CSE: MGIC reserved) (“MagicMed” or the “Company“) announced today a collaboration among the Company, Dr. Suran Goonatilake and Dr. Eric Nyberg, renowned thought leaders in artificial intelligence (“AI“). Together the parties are building PsyAITM, a tool designed to provide comprehensive, pharmaceutical design, manufacturing, pharmacology predictive and validating methodologies in an effort to modernize psychedelic medicine.
February’s Psychedelic Capital Investigates Institutional Vs Retail Investor Impact
Microdose Psychedelic Insights (“Microdose”), a leader in B2B psychedelic intelligence, to present in a partnership with The Conscious Fund the most active VC in psychedelic space, the next edition of Psychedelic Capital.
The Conscious Acquisition Company
Exchange Listing, LLC and The Conscious Fund announce their partnership and the creation of The Conscious Acquisition Company. The new venture is a range of Special Purpose Acquisition Company’s (SPACs) aimed to create long-term value in psychedelic medicine.
Proclinical Executive and The Conscious Fund Partner to Boost Psychedelic Start-Ups
Psychedelic medicine start-ups are set to benefit from a newly-formed partnership between life science executive search specialists, Proclinical Executive, and venture capital investors, The Conscious Fund.
The Future of Mental Health and Addiction Therapy: Why Capital is Flowing into Psychedelics
Psychedelics is one segment of the healthcare industry that is rapidly researching and developing transformative products that may have the potential to provide treatment to those suffering from mental illnesses, addiction, and other often overlooked and stigmatized conditions.
Psilocybin startup visualized by NHL enforcer and Blackhawk champ raises $4 million
Co-founded by two-time National Hockey League (NHL) champion-turned mental health advocate Daniel Carcillo and cannabis serial entrepreneur Chad Bronstein, Wesana will allocate fresh funding towards the use of psychedelics in the treatment of traumatic brain injury.
GHP Noetic Science-Psychedelic Pharma and Diamond Therapeutics Announce Proposed Qualifying Transaction
GHP Noetic Science-Psychedelic
Pharma Inc. (TSXV:PSYF.P) (“GHP”), a capital pool company, and Diamond
Therapeutics Inc. (“Diamond”), a psychedelic drug development company focused on low-dose therapies for mental health, are pleased to announce the signing of a letter of intent dated effective February 2, 2021 (the “LOI”).
Bexson Biomedical Raises $4.8 Million In Oversubscribed Series A
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Learn more.
Wesana Health Closes $4 Million Convertible Note Round
The $4 million round, led by The Conscious Fund and Ambria Capital, LLC, provides funding to support the Company’s entry into the emerging psychedelics space. Learn more.
From NHL Enforcer To CEO: Daniel Carcillo’s New Company Wants To Treat Traumatic Brain Injury With Psilocybin
The newest CEO in the psychedelics space is a former NHL enforcer who wants to treat traumatic brain injury with psilocybin. Learn more.
Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founding Partner at The Conscious Fund, Henri Sant-Cassia.
David and Henri take some time to discuss the reason behind finding The Conscious Fund, and what they will be working on to push forward in the coming year on the latest episode of Psychedelic Spotlight.
MEC Announces Letter of Intent To Acquire Albert Labs, A European Psychedelic Drug Researcher & Developer
ME Resources Corp. is pleased to announce that it has entered into a letter of intent with Albert Labs Inc.
MagicMed Completes Upsized, Oversubscribed Private Placement
MagicMed has completed an upsized and oversubscribed $8.1 million private placement, with investors including The Conscious Fund
Universal Ibogaine engages The Conscious Fund as strategic advisor
“We are excited that TCF will be involved with UI as a key strategic advisor as we continue to build out our business plan, and undertake our pending go-public process,” said UI CEO Jeremy Weate.
Due Diligence Critical for Emerging Psychedelics Space
As the potential of psychedelics continues to bring new investors to the sector, a group of experts examined the amount of research needed before putting money into the market.
Recent Momentum Shows Psychedelic Medicine “Isn’t a Pipe Dream”
“It’s shown to the world what insiders have known for a long time — that this vision of bringing psychedelic medicine to the world isn’t a pipe dream, it’s very real and it’s happening now,” Hoyos said.
‘Psychedelics renaissance’: Startups turning magic mushrooms into medicine are racing to go public
“I think valuations are going to start reflecting that sooner rather than later,” said Hoyos, who added that he thinks the valuations of some of the companies that have gone public as of late haven’t reached their maximum potential yet.
New Wave: To Provide Sponsorship for the Documentary “The World on Drugs”
They are proud to support the novel efforts by the Microdose team to explore psychedelics and mental health across borders and through a rich, diverse lens.
Proactive ONE2ONE Virtual Investor Forum, Investing in Psychedelics, The Path to Big Pharma Webinar
Proactive Investors Present One2One conference on Psychedelics featuring The Conscious Fund, MagicMed and Field Trip.
‘An Evolution Of What’s Possible:’ Panel Explores Blurring Of Psychedelics And Technology
Although the speakers focused on how technology can enhance a psychedelic experience or make one more accessible, they stressed that tech should not supplant natural substances.
“An Evolution of What’s Possible:” Panel Explores Blurring of Psychedelics and Technology
The panel discussion was part of a larger “Psychedelic Capital” webinar presented by Microdose Psychedelic Insights, a company that coordinates events focused on the psychedelic industry.
5 Ways Technology Is Powering The Psychedelic Movement
Thousand-year-old treatments are being fueled by future innovations.
Microdose Presents Psychedelic Capital – A Virtual Investment Conference Highlighting Prominent Industry Players
This online event programming is dedicated to providing investment grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe.
Psychedelics association to bridge medical establishment and industry gap
Leaders in the field of psychedelic medicine have joined forces to create the global Psychedelic Medicine Association (PMA), which aims to bridge the gap between the medical establishment, patients, and the industry.
Investment Fund Seeks Cultural Reset for Psychedelics
As the psychedelics investment community begins to come into focus, one association is working to create an all-around hub for investors looking to enter the space.
Ketamine Media Creates Strategic Partnership With Microdose Psychedelic Insights for the Ketamine Conference – a Molecular Masterclass
Ketamine Media, the first digital agency dedicated to raising awareness for the clinical use of ketamine, announced today the launch of a new strategic partnership with Microdose Psychedelic Insights for their upcoming Ketamine Conference – A Molecular Masterclass
The Ketamine Conference: A Molecular Masterclass
The Ketamine Conference: A Molecular Masterclass is set to take place today, featuring a host of experts in the delivery of ketamine therapy for resistant conditions such as PTSD, depression, and anxiety.
Psychedelics M&A Could be Motivated by FOMO
One business lawyer focused on mergers and acquisitions (M&A) expects to see large entities, such as pharmaceutical companies, enter the psychedelics space sooner rather than later.
Stigma Podcast #63 – Psychedelic Focused VC: The Conscious Fund with Richard Skaife
Micro-dosing with Zeifmans: Short podcasts demystifying the business of psychedelics
Join Zeifmans Partner, Larry Zeifman, and weekly guest thought leaders in the psychedelics space, for a 6 part series, on exploring the business of psychedelics. New episode drops every Wednesday.
Psychedelic Masterclass Spotlights Ketamine as a Novel Mental Health Medicine
Microdose Psychedelic Insights, along with Bexson Biomedical, The Conscious Fund, and Ketamine Media presents The Ketamine Conference: A Molecular Masterclass, a two-day virtual conference.
The Conscious Fund seizing early-stage opportunities in psychedelic medicines
The Conscious Fund’s Henri Sant-Cassia tells Proactive London’s Andrew Scott they’re looking at plant-based medicines with the current focus being on psychedelic medicines – including drug discovery plays and clinic plays around mental health and addiction.
The Conscious Fund eyes opportunity in psychedelic medicine space
The fund is currently focusing on compounds such as magic mushrooms, ketamine and MDMA as possible treatments for mental illness and addiction
The Conscious Fund’s Richard Skaife looks ahead to Psychedelic Capital investor event
Four companies will be presenting – HAVN Life, MindSet Pharma, Field Trip and Pure Extractions.